Oxypurinol is under clinical development by XORTX Therapeutics and currently in Phase II for Polycystic Kidney Disease. According to GlobalData, Phase II drugs for Polycystic Kidney Disease have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Oxypurinol’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Oxypurinol (XRX-008) is under development for the treatment of autosomal dominant polycystic kidney disease (ADPKD). It acts by targeting xanthine oxidase. It was also under development for the treatment of diabetes, hereditary hyporuicemia and metabolic syndrome. The product is administered orally.
XORTX Therapeutics overview
XORTX Therapeutics (XORTX) is a biopharmaceutical company that discovers and develops drugs to treat kidney diseases. It is investigating XRx-101, a formulation of oxypurinol against kidney, lung injury, and health effects associated with coronavirus infection; XRx-008 drug for the treatment of autosomal dominant polycystic kidney disease (ADPKD). The company is also evaluating XRx-221 drug in partnership with Teijin Pharma Ltd to treat type 2 diabetic nephropathy (T2DN). XORTX is headquartered in Calgary, Alberta, Canada.
For a complete picture of Oxypurinol’s drug-specific PTSR and LoA scores, buy the report here.